Orchestra BioMed

OBIO

Market cap $210M

Overview Fund Trends Analyst Outlook Journalist POV

3.89 USD

--0.01

0.26%

At close Updated Oct 21, 4:00 PM EDT

Pre-market

After hours

3.89

0.00

1 day

-0.26%

5 days

6.87%

1 month

58.78%

3 months

23.1%

6 months

36.97%

Year to date

-27.7%

1 year

-28.1%

5 years

-64.51%

10 years

-65.88%

About: Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Employees: 70

Healthcare Biotechnology